GITNUX MARKETDATA REPORT 2024

Pregabalin Onset Efficacy For Nerve Pain Statistics

Pregabalin has demonstrated significant onset efficacy for nerve pain based on statistical analysis of relevant clinical trials.

With sources from: ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, accessdata.fda.gov, cochranelibrary.com and many more

Statistic 1

Pregabalin is effective in reducing neuropathic pain within the first week of treatment in 48% of patients.

Statistic 2

Pregabalin can improve sleep disturbances in 63% of patients with nerve pain within the first week of treatment.

Statistic 3

In clinical trials, the median time to onset of significant pain relief for Pregabalin was 4 days for nerve pain.

Statistic 4

On average, patients treated with Pregabalin experienced a mean reduction of nerve pain score by 2.49.

Statistic 5

A total of 35% of patients report a reduction in nerve pain with Pregabalin after one week of treatment.

Statistic 6

The efficacy of Pregabalin for managing diabetic peripheral neuropathic pain is 50%.

Statistic 7

By 12 weeks, nearly 60% of patients experience a significant reduction in nerve pain with Pregabalin.

Statistic 8

Pregabalin reduced weekly mean pain scores by at least 50% in 45% of patients with neuropathic pain.

Statistic 9

After 4-6 weeks of treatment, pregabalin reduced the pain intensity by approximately 2.2 points on a 10-point scale.

Statistic 10

Pregabalin has been found to reduce sleep interference score by an average of 2.63 in patients with neuropathic pain.

Statistic 11

The duration of exposure ranged from 1 day to 1462 days with an average duration of exposure of 274 days in clinical trials.

Statistic 12

Pregabalin was associated with a greater number of adverse events than alternative adjunctive drugs (26% vs 14%).

Statistic 13

An estimated 246.2 patients per 1000 would benefit from pregabalin compared with 175 per 1000 treated with placebo.

Sources Icon Sources

In this post, we explore the efficacy of Pregabalin in managing nerve pain, backed by a comprehensive analysis of key statistics from clinical trials. From the rapid onset of pain relief to improvements in sleep disturbances, we delve into the tangible benefits experienced by patients undergoing Pregabalin treatment.

Statistic 1

"Pregabalin is effective in reducing neuropathic pain within the first week of treatment in 48% of patients."

Sources Icon

Statistic 2

"Pregabalin can improve sleep disturbances in 63% of patients with nerve pain within the first week of treatment."

Sources Icon

Statistic 3

"In clinical trials, the median time to onset of significant pain relief for Pregabalin was 4 days for nerve pain."

Sources Icon

Statistic 4

"On average, patients treated with Pregabalin experienced a mean reduction of nerve pain score by 2.49."

Sources Icon

Statistic 5

"A total of 35% of patients report a reduction in nerve pain with Pregabalin after one week of treatment."

Sources Icon

Statistic 6

"The efficacy of Pregabalin for managing diabetic peripheral neuropathic pain is 50%."

Sources Icon

Statistic 7

"By 12 weeks, nearly 60% of patients experience a significant reduction in nerve pain with Pregabalin."

Sources Icon

Statistic 8

"Pregabalin reduced weekly mean pain scores by at least 50% in 45% of patients with neuropathic pain."

Sources Icon

Statistic 9

"After 4-6 weeks of treatment, pregabalin reduced the pain intensity by approximately 2.2 points on a 10-point scale."

Sources Icon

Statistic 10

"Pregabalin has been found to reduce sleep interference score by an average of 2.63 in patients with neuropathic pain."

Sources Icon

Statistic 11

"The duration of exposure ranged from 1 day to 1462 days with an average duration of exposure of 274 days in clinical trials."

Sources Icon

Statistic 12

"Pregabalin was associated with a greater number of adverse events than alternative adjunctive drugs (26% vs 14%)."

Sources Icon

Statistic 13

"An estimated 246.2 patients per 1000 would benefit from pregabalin compared with 175 per 1000 treated with placebo."

Sources Icon

Interpretation

In conclusion, the statistics presented demonstrate that Pregabalin is an effective treatment option for reducing nerve pain and improving sleep disturbances in patients with neuropathic pain within the first week of treatment. The data suggest that Pregabalin has a rapid onset of action, with a substantial proportion of patients experiencing significant pain relief within the initial days of treatment. Furthermore, the overall efficacy of Pregabalin in managing nerve pain, particularly diabetic peripheral neuropathic pain, is notable, with a majority of patients experiencing considerable pain reduction by 12 weeks of treatment. However, it is important to consider the higher incidence of adverse events associated with Pregabalin compared to alternative drugs, highlighting the need for careful monitoring and individualized treatment approaches.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.

Submit Your Own Statistic Data

Would you like to submit your own researched statistics on this topic? You are welcome to use the form below and submit your suggestion to us. We will check the source and approve it if necessary.

... Before You Leave, Catch This! 🔥

Your next business insight is just a subscription away. Our newsletter The Week in Data delivers the freshest statistics and trends directly to you. Stay informed, stay ahead—subscribe now.

Sign up for our newsletter and become the navigator of tomorrow's trends. Equip your strategy with unparalleled insights!